TWA1, also known as Tudor domain-containing protein 7 (TDRD7), is a protein encoded by the TWA1 gene. It is a component of the chromatin and has been implicated in multiple cellular processes due to its involvement in the regulation of gene expression.The protein contains a Tudor domain, which is associated with the recognition of and binding to specific epigenetic marks, such as methylated arginine and lysine residues on histones. These epigenetic marks are crucial for the regulation of chromatin structure and function, influencing gene expression patterns by either repressing or activating transcription.
TWA1 is also recognized for its role in the DNA damage response. It is involved in the repair of DNA double-strand breaks by non-homologous end joining (NHEJ), which is critical for maintaining genomic stability. Furthermore, TWA1 interacts with components of the spliceosome, the complex responsible for RNA splicing, thereby potentially influencing post-transcriptional modification and control of gene expression.In addition to its nuclear functions, TWA1 has been observed in the cytoplasm, where it may play a role in cytoskeletal organization. Its interaction with microtubules suggests a potential involvement in cell division and migration, although the details of these interactions are not fully understood.TWA1 is also a member of the RUVBL1-RUVBL2 complex, which has ATPase activity and is involved in various cellular processes, including transcription regulation, DNA repair, and the assembly of protein complexes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor, could indirectly affect TWA1 by altering protein degradation pathways and the ubiquitin-proteasome system. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor, potentially influencing TWA1 by modulating proteasomal degradation of proteins. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits protein synthesis, could indirectly affect TWA1 by altering the overall protein synthesis and degradation balance. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor, potentially affecting TWA1 by modulating cellular growth and protein synthesis pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor, potentially affecting TWA1 activity by modulating the PI3K/Akt signaling pathway, which is involved in various cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor, potentially affecting TWA1 by modulating the MAPK/ERK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, could indirectly influence TWA1 activity through the PI3K/Akt pathway. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Chemotherapeutic agent that induces DNA damage, potentially influencing TWA1 expression through DNA damage response pathways. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Topoisomerase II inhibitor, can induce DNA damage and potentially influence TWA1 through DNA damage response mechanisms. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Chemotherapeutic agent causing DNA crosslinking, potentially affecting TWA1 through DNA damage response pathways. | ||||||